ラクオリア創薬
4579
東証グロース
医薬品
ラクオリア創薬の決算推移
損益計算書
(単位:百万円)
2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | |
---|---|---|---|---|---|---|---|---|---|---|
売上高 | 153 | 145 | 705 | 1,419 | 744 | 1,702 | 1,107 | 2,776 | 2,918 | 1,901 |
売上原価 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
売上総利益 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
販管費 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
営業利益 | -2,184 | -1,865 | -760 | -151 | -1,076 | -16 | -487 | 707 | 866 | -338 |
営業外収益 | 87 | 98 | 94 | 84 | 45 | 49 | 34 | 177 | 76 | 88 |
営業外費用 | 19 | 29 | 55 | 14 | 34 | 11 | 76 | 21 | 38 | 44 |
経常利益 | -2,117 | -1,796 | -721 | -81 | -1,065 | 21 | -528 | 863 | 904 | -294 |
特別利益 | 1,549 | 65 | N/A | 20 | 4 | 5 | 9 | 16 | 14 | N/A |
特別損失 | 64 | 118 | 2 | 0 | 17 | N/A | 9 | N/A | 67 | 0 |
当期純利益 | -639 | -1,855 | -729 | -59 | -1,105 | 5 | -607 | 755 | 723 | -324 |
貸借対照表
(単位:百万円)
2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | |
---|---|---|---|---|---|---|---|---|---|---|
資産 | 5,216 | 4,752 | 4,019 | 5,064 | 4,052 | 4,836 | 4,251 | 5,234 | 6,257 | 6,871 |
流動資産 | 3,272 | 2,707 | 1,806 | 3,322 | 1,962 | 3,067 | 2,834 | 4,003 | 4,822 | 4,956 |
現金及び預金 | 1,903 | 1,840 | 1,427 | 2,268 | 1,671 | 2,174 | 1,394 | 2,345 | 3,675 | 3,714 |
売上債権 | 20 | 72 | 58 | 448 | 0 | 747 | 530 | 1,205 | N/A | N/A |
棚卸資産 | 8 | 7 | 7 | 5 | 6 | 5 | 6 | 10 | 8 | 147 |
固定資産 | 1,944 | 2,044 | 2,212 | 1,741 | 2,090 | 1,769 | 1,417 | 1,230 | 1,435 | 1,915 |
負債 | 530 | 237 | 231 | 176 | 195 | 215 | 240 | 446 | 760 | 751 |
流動負債 | 421 | 200 | 190 | 148 | 164 | 183 | 186 | 400 | 493 | 389 |
仕入債務 | N/A | N/A | N/A | 1 | N/A | 34 | 41 | 45 | 128 | 54 |
固定負債 | 108 | 37 | 41 | 27 | 30 | 32 | 53 | 45 | 266 | 362 |
純資産 | 4,685 | 4,514 | 3,788 | 4,887 | 3,857 | 4,620 | 4,011 | 4,788 | 5,496 | 6,120 |
利益剰余金 | -8,713 | -10,422 | -729 | -786 | -1,891 | -100 | -707 | 49 | 773 | 449 |
自己株式 | N/A | N/A | N/A | -1 | -1 | -1 | -1 | -1 | -1 | -1 |